What to expect from Haemonetics's (HAE) Q3 earnings

What happened

Haemonetics is scheduled to report its third-quarter earnings this Thursday before the market opens. Analysts expect revenue to rise 5.4% year over year, compared with a 5.3% decline in the same quarter last year. Over the past 30 days, analysts generally reconfirmed their estimates.

Confirmed

Global impact / market context

The report will show whether Haemonetics can turn the expected return to revenue growth into actual sales. Revenue above or below expectations could influence investor views of its growth outlook, while the article provides no current forecast for profit or costs.

Analyst inference

Last quarter, Haemonetics reported revenue of $339.4 million, up 5.6% year over year, and beat analysts’ revenue and earnings-per-share estimates; earnings per share is profit allocated to each share. Peer results were mixed, offering limited clues for this quarter.

Confirmed

What to watch

1. Compare reported third-quarter revenue growth with the 5.4% year-over-year increase analysts expect; the result will indicate whether the anticipated recovery from last year’s decline materialized. Analyst inference
2. Check whether Haemonetics beats or misses analysts’ revenue estimates and earnings-per-share estimates; the article reports both measures were exceeded last quarter. Analyst inference
3. Review any company outlook or explanation for sales trends, costs, or demand, since the supplied article gives no management forecast or detail about factors driving expected growth. Analyst inference

Evidence

• stockstory.org